Literature DB >> 9326238

Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome.

K Horikawa1, H Nakakuma, T Kawaguchi, N Iwamoto, S Nagakura, T Kagimoto, K Takatsuki.   

Abstract

Bone marrow (BM) hypoplasia is a major cause of death in paroxysmal nocturnal hemoglobinuria (PNH). However, little is known about the molecular events leading to the hypoplasia. Considering the close pathologic association between PNH and aplastic anemia (AA), it is suggested that a similar mechanism operates in the development of their BM failure. Recent reports have indicated apoptosis-mediated BM suppression in AA. It is thus conceivable that apoptosis also operates to cause BM hypoplasia in PNH. If this is the case, PNH clones need to survive apoptosis and show considerable expansion leading to clinical manifestations. We report here that granulocytes obtained from 11 patients with PNH were apparently less susceptible than those from 20 healthy individuals to both spontaneous apoptosis without any ligands and that induced by anti-FAS (CD95) antibody in vitro. The patients' BM CD34+ cells were also resistant to apoptosis induced by treatment with tumor necrosis factor-alpha, interferon-gamma, and subsequently with anti-FAS antibody. In lymphocytes, the pathologic resistance was not discriminated from inherent resistance to apoptosis. Granulocytes from 13 patients with AA and 12 patients with myelodysplastic syndrome (MDS) exhibited similar resistance to apoptosis. CD34+ cells from MDS-BM also showed similar tendency. Thus, the comparative resistance to apoptosis supports the pathogenic implication of apoptosis in marrow injury of PNH and related stem cell disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326238

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  Pathogenesis of selective expansion of PNH clones.

Authors:  Hideki Nakakuma; Tatsuya Kawaguchi
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

2.  Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals.

Authors:  D J Araten; K Nafa; K Pakdeesuwan; L Luzzatto
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 3.  New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.

Authors:  Tatsuya Kawaguchi; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 4.  Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems.

Authors:  Wendell F Rosse; Junichi Nishimura
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

5.  Impaired growth and elevated fas receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal hemoglobinuria.

Authors:  R Chen; S Nagarajan; G M Prince; U Maheshwari; L W Terstappen; D R Kaplan; S L Gerson; J M Albert; D E Dunn; H M Lazarus; M E Medof
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

6.  Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.

Authors:  Maria Ximeri; Athanasios Galanopoulos; Mirjam Klaus; Agapi Parcharidou; Krinio Giannikou; Maria Psyllaki; Argyrios Symeonidis; Vasiliki Pappa; Zafiris Kartasis; Dimitra Liapi; Eleftheria Hatzimichael; Styliani Kokoris; Penelope Korkolopoulou; Constantina Sambani; Charalampos Pontikoglou; Helen A Papadaki
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

7.  Effect of arsenic, cadmium and lead on the induction of apoptosis of normal human mononuclear cells.

Authors:  H de la Fuente; D Portales-Pérez; L Baranda; F Díaz-Barriga; V Saavedra-Alanís; E Layseca; R González-Amaro
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

Review 8.  Oxidative stress and the myelodysplastic syndromes.

Authors:  Morag J Farquhar; David T Bowen
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

9.  Lymphocytes with aberrant expression of Fas or Fas ligand attenuate immune bone marrow failure in a mouse model.

Authors:  Stephanie O Omokaro; Marie J Desierto; Michael A Eckhaus; Felicia M Ellison; Jichun Chen; Neal S Young
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

10.  Neutral evolution in paroxysmal nocturnal hemoglobinuria.

Authors:  David Dingli; Lucio Luzzatto; Jorge M Pacheco
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.